Compounds > 2-amino-4,5,6,7-tetrahydrobenzothiazole
Page last updated: 2024-11-05

2-amino-4,5,6,7-tetrahydrobenzothiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-amino-4,5,6,7-tetrahydrobenzothiazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID18046
CHEMBL ID1178797
SCHEMBL ID558522
MeSH IDM0535605

Synonyms (47)

Synonym
HMS1681A20
BB 0218031
2-amino-4,5-tetramethylenethiazole
4,5,6,7-tetrahydro-2-aminobenzothiazole
benzothiazole, 4,5,6,7-tetrahydro-2-amino-
4,5,6,7-tetrahydro-benzothiazol-2-ylamine
2-amino-4,5,6,7-tetrahydrobenzothiazole, 97%
AE-848/32603050
4,5,6,7-tetrahydro-1,3-benzothiazol-2-ylamine
OPREA1_480082
4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine
STK346851
AKOS000103471
F1040-0006
AB00682069-01
AKOS002270771
2933-29-1
CHEMBL1178797
EN300-02259
4,5,6,7-tetrahydrobenzothiazole-2-ylamine
FT-0634565
2R-1130
SCHEMBL558522
2-amino-4,5,6,7-tetrahydrobenzothiazole
4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine
2-amino4,5,6,7-tetrahydro-benzothiazole
4,5,6,7-tetrahydro-benzothiazol-2-yl-amine
2-amino-4,5,6,7-tetrahydrobenzthiazole
mfcd00022851
SY007341
benzothiazole, 2-amino-4,5,6,7-tetrahydro-
2-benzothiazolamine, 4,5,6,7-tetrahydro-
4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine #
4,5,6,7-tetrahydrobenzothiazol-2-amine
AC-24354
J-514052
DTXSID20183566
J-017478
SR-01000512237-1
sr-01000512237
2-imino-2,3,4,5,6,7-hexahydrobenzothiazole
4,5,6,7-tetrahydrobenzothiazol-2-ylamine
4,5,6,7-tetrahydro-2-aminobenzothiazol
AMY20159
CS-0043951
SB36421
F13660
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1426916Inhibition of recombinant human C-terminal His-tagged PHGDH (1 to 533 residues) expressed in Escherichia coli assessed as reduction in NADH formation at 100 uM using 3-phosphoglycerate as substrate preincubated measured for 7 mins in presence of NAD+ by s2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
α-Ketothioamide Derivatives: A Promising Tool to Interrogate Phosphoglycerate Dehydrogenase (PHGDH).
AID1918453Binding affinity to KRAS G12V/S39C-BIT mutant (unknown origin) assessed as dissociation constant by HSQC NMR spectroscopy analysis2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS
AID744570Antiangiogenic activity against human HUVEC cells assessed as inhibition of [3H]thymidine incorporation incubated for 24 hrs prior to [3H]thymidine addition measured after 6 hrs by microbeta counting analysis2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Tricyclic thiazoles are a new class of angiogenesis inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's6 (75.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.68 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
toluene
methylbenzene : Any alkylbenzene that is benzene substituted with one or more methyl groups.		2.0510methylbenzene;
toluenes;
volatile organic compound		cholinergic antagonist;
fuel additive;
neurotoxin;
non-polar solvent
quinone
benzoquinone : The simplest members of the class of benzoquinones, consisting of cyclohexadiene which is substituted by two oxo groups.. 1,4-benzoquinone : The simplest member of the class of 1,4-benzoquinones, obtained by the formal oxidation of hydroquinone to the corresponding diketone. It is a metabolite of benzene.. quinone : Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included).		2.15101,4-benzoquinonescofactor;
human xenobiotic metabolite;
mouse metabolite
pifithrin
pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source		2.0510aromatic ketone
1,4-naphthoquinone
naphthoquinone : A polycyclic aromatic ketone metabolite of naphthalene.. 1,4-naphthoquinone : The parent structure of the family of 1,4-naphthoquinones, in which the oxo groups of the quinone moiety are at positions 1 and 4 of the naphthalene ring. Derivatives have pharmacological properties.		2.15101,4-naphthoquinones
sotorasib
sotorasib: a KRAS(G12C) inhibitor. sotorasib : A pyridopyrimidine that is pyrido[2,3-d]pyrimidin-2(1H)-one substituted by 4-methyl-2-(propan-2-yl)pyridin-3-yl, (2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl, fluoro and 2-fluoro-6-hydroxyphenyl groups at positions 1, 4, 6 and 7, respectively. It is approved for the treatment of patients with non-small cell lung cancer having KRAS(G12C) mutations.		2.4110acrylamides;
methylpyridines;
monofluorobenzenes;
N-acylpiperazine;
phenols;
pyridopyrimidine;
tertiary amino compound;
tertiary carboxamide		antineoplastic agent
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
Benign Neoplasms
[description not available]		02.6320
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.6320
Idiopathic Parkinson Disease
[description not available]		02.1110
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)		02.1110